221 related articles for article (PubMed ID: 34863994)
1. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
Shohan M; Nashibi R; Mahmoudian-Sani MR; Abolnezhadian F; Ghafourian M; Alavi SM; Sharhani A; Khodadadi A
Eur J Pharmacol; 2022 Jan; 914():174615. PubMed ID: 34863994
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Shahrbaf MA; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
[TBL] [Abstract][Full Text] [Related]
3. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
Ozsurekci Y; Oygar PD; Gürlevik SL; Kesici S; Ozen S; Kurt Sukur ED; Gülhan B; Topaloglu R; Bayrakci B; Cengiz AB
Pediatr Nephrol; 2021 Nov; 36(11):3771-3776. PubMed ID: 34021797
[TBL] [Abstract][Full Text] [Related]
4. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
[TBL] [Abstract][Full Text] [Related]
7. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
8. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center.
McCoy JA; Short WR; Srinivas SK; Levine LD; Hirshberg A
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100164. PubMed ID: 32838267
[No Abstract] [Full Text] [Related]
9. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
10. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
Hong YN; Xu J; Sasa GBK; Zhou KX; Ding XF
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):541-548. PubMed ID: 33506946
[TBL] [Abstract][Full Text] [Related]
12. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
[TBL] [Abstract][Full Text] [Related]
13. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1).
Qaseem A; Yost J; Etxeandia-Ikobaltzeta I; Abraham GM; Jokela JA; Forciea MA; Miller MC; Humphrey LL; ; Centor RM; Andrews R; Haeme R; Kansagara DL; Marcucci M
Ann Intern Med; 2021 Feb; 174(2):229-236. PubMed ID: 33017175
[TBL] [Abstract][Full Text] [Related]
14. [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.].
Cruciani F; Amato L; De Crescenzo F; Mitrova Z; Saulle R; Vecchi S; Davoli M
Recenti Prog Med; 2021 Mar; 112(3):195-206. PubMed ID: 33687358
[TBL] [Abstract][Full Text] [Related]
15. Remdesivir (Veklury) for COVID-19.
Med Lett Drugs Ther; 2020 Nov; 62(1612):186-188. PubMed ID: 33443491
[No Abstract] [Full Text] [Related]
16. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
Piscoya A; Ng-Sueng LF; Parra Del Riego A; Cerna-Viacava R; Pasupuleti V; Roman YM; Thota P; White CM; Hernandez AV
PLoS One; 2020; 15(12):e0243705. PubMed ID: 33301514
[TBL] [Abstract][Full Text] [Related]
18. Liver injury in remdesivir-treated COVID-19 patients.
Zampino R; Mele F; Florio LL; Bertolino L; Andini R; Galdo M; De Rosa R; Corcione A; Durante-Mangoni E
Hepatol Int; 2020 Sep; 14(5):881-883. PubMed ID: 32725454
[No Abstract] [Full Text] [Related]
19. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
Trkulja V
Eur J Clin Pharmacol; 2021 Jun; 77(6):935-937. PubMed ID: 33404753
[No Abstract] [Full Text] [Related]
20. Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials.
Kow CS; Aldeyab M; Hasan SS
J Med Virol; 2021 Apr; 93(4):1860-1861. PubMed ID: 33118617
[No Abstract] [Full Text] [Related]
[Next] [New Search]
